With data from the new Motley Fool CAPS investment research service, we've looked at some poorly rated stocks that have shown some life in the previous month. Today we're right back at it again, considering another collection of lowly outperformers. Are these poised to skyrocket, or just enjoying their swan song?
Here are this week's magnificent seven, as identified by your fellow Fools on CAPS. Each of the companies below had been given a one-star rating (the lowest) by our community of investors just 30 days ago:
|
Stock
|
30-day return
|
One-year return
|
|
Imergent (AMEX: IIG )
|
60.8%
|
469.4%
|
|
Interoil (AMEX: IOC )
|
50.7%
|
15.1%
|
|
Fuel System Solutions (Nasdaq: FSYS )
|
49.5%
|
249.2%
|
|
Orckit
Communications (Nasdaq: ORCT )
|
46.3%
|
-44.7%
|
|
Trustreet
Properties (NYSE: TSY )
|
36%
|
19%
|
|
StemCells (Nasdaq: STEM )
|
35.9%
|
-29.3%
|
|
ISIS Pharmaceuticals (Nasdaq: ISIS )
|
35.4%
|
128.2%
|
Data provided from Motley Fool CAPS as of Nov. 15.
In spite of these tasty one-month returns, four of these stocks are still rated just one star today. The other three have gotten a little more respect, though. The $180-million-market-cap Orckit, which develops telecom transport equipment for high-bandwidth video services, has been bumped up to three stars. Both StemCells, which, well, works with stem-cell therapeutics, and ISIS, a biopharmaceutical company, were granted two-star status.
Though recent raters of Orckit have kept mum, CAPS user ztur commented back in September that the company has a lot of potential for its low price. It's also notable that all five All-Stars have given Orckit the thumbs up -- including GrumpyOldGuy, who just gave the company the nod last Friday. Community members are split on whether the new Democratic Congress will be the panacea for StemCells, or whether it's a mirage. Finally, ISIS popped on some good phase 2 data, attracting 18 CAPS members to the stock in the last two days. Though most were giving the thumbs up, two All-Stars came to the table with a big, fat "not so much" for ISIS.
Is the above information, on its own, enough for you to run out and start buying up these stocks like a kid in a candy store? Of course not! But they might be excellent candidates for further due diligence. In the meantime, get in the game and get yourself heard. You'll also be able to read timely analysis from our community, and perhaps offer your own pitch for one of these stocks. It's entirely free, and it's definitely a place where "the more the merrier" is actually true. Click here to get started.
For additional one-star stocks:
Fool contributor Matt Koppenheffer didn't see these particular moves coming, but he is rarely surprised at Mr. Market's general tomfoolery. He does not own shares of any of the companies mentioned. The Fool's disclosure policy is always expected.
RSS Headlines
Fool UK